AANEM News Express

AANEM News Express

Genetic Sequencing for LGMD Patients

2/11/2015
 
Emory University is partnering with a consortium of LGMD disease foundations (LGMD-diagnosis.org). Their goal is to do diagnostic sequencing research for patients suspected of having LGMD or other muscular dystrophy with similar clinical presentations.
 
Physicians may apply online using ALDA (Automated LGMD Diagnostic Assistant) to determine their patient's eligibility for the program. Eligible patients are asked to complete a questionnaire, provide consent, and send in a saliva sample for sequencing of 35 genes known to be involved in various forms of muscular dystrophy.
 
The sequencing is done at no cost to the patient. The patient will not be obligated or automatically enrolled as a subject in any program outside of the LGMD-diagnosis.org program. Patients with diseases covered by an existing LGMD disease organization may be contacted by that organization with information about their services.
 
Currently only individuals who live in the U.S. are eligible for this no-cost genetic sequencing program. For more information about this program go to www.lgmd-diagnosis.org
 
Note: AANEM is not directly involved in this research study.


View Related News Stories:

  Practice


Recent AANEM News

President Biden’s Initial Health Care Priorities

Science News: Placebo Effect in Chronic Inflammatory Demyelinating Polyneuropathy: The PATH Study and a Systematic Review

2021-2022 AANEM & ABEM Committee Volunteers Needed

COVID-19 Vaccine: AANEM Publishes Guidance for Patients with NMDs

2021 AANEM Annual Meeting: Funds Available for Physicians from Economically Developing Countries to Attend





Advertisement

ABEM

Advertisement

Donate

Advertisement

SAE